id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-N-0196-0055,FDA,FDA-2003-N-0196,"Initial Determination and Feedback Letter from FDA/CDER to L'Oreal USA Products, Inc re Time and Extent Application (TEA) Drometrizole Trisiloxane for use in Over-the-Counter (OTC) Sunscreens",Other,Letter(s),2014-08-29T04:00:00Z,2014,8,2014-08-29T04:00:00Z,,2014-08-29T21:20:12Z,,0,0,09000064818511a4
FDA-2003-N-0196-0054,FDA,FDA-2003-N-0196,"Letter from FDA/CDER to BASF AG (Morgan, Lewis & Bockius LLP)",Other,Letter(s),2014-06-23T04:00:00Z,2014,6,2014-06-23T04:00:00Z,,2014-06-23T18:14:09Z,,0,0,090000648175c494
FDA-2003-N-0196-0053,FDA,FDA-2003-N-0196,"Supplement from BASF AG (Morgan Lewis & Bockius, LLP)",Other,Supplement (SUP),2014-06-11T04:00:00Z,2014,6,2014-06-11T04:00:00Z,,2014-06-11T15:51:37Z,,0,0,090000648048b765
FDA-2003-N-0196-0051,FDA,FDA-2003-N-0196,"Data and Information from BASF AG (Morgan Lewis & Bockius, LLP)",Other,Submission of Information,2014-06-11T04:00:00Z,2014,6,2014-06-11T04:00:00Z,,2014-06-11T15:48:23Z,,0,0,090000648173afac
FDA-2003-N-0196-0052,FDA,FDA-2003-N-0196,"Supplement from BASF AG (Morgan Lewis & Bockius, LLP)",Other,Supplement (SUP),2014-06-11T04:00:00Z,2014,6,2014-06-11T04:00:00Z,,2014-06-11T15:49:59Z,,0,0,090000648048b660
FDA-2003-N-0196-0048,FDA,FDA-2003-N-0196,Letter from Symrise North America Cosmetic Division,Other,Letter(s),2014-06-09T04:00:00Z,2014,6,2014-06-09T04:00:00Z,,2014-06-09T21:19:55Z,,0,0,090000648048b606
FDA-2003-N-0196-0047,FDA,FDA-2003-N-0196,"Letter from Buchanan Ingersoll to the Division of Over-The-Counter Drug Products, July 25, 2003",Other,Letter(s),2014-06-09T04:00:00Z,2014,6,2014-06-09T04:00:00Z,,2014-06-09T21:12:37Z,,0,0,090000648048b600
FDA-2003-N-0196-0049,FDA,FDA-2003-N-0196,"Letter from FDA/CDER to BASF AG (Morgan, Lewis & Bockius LLP)",Other,Letter(s),2014-06-09T04:00:00Z,2014,6,2014-06-09T04:00:00Z,,2014-06-09T21:29:26Z,,0,0,090000648048b61b
FDA-2003-N-0196-0050,FDA,FDA-2003-N-0196,"Supplement from BASF AG (Morgan Lewis & Bockius, LLP)",Other,Supplement (SUP),2014-06-09T04:00:00Z,2014,6,2014-06-09T04:00:00Z,,2014-06-09T22:01:14Z,,0,0,090000648048b622
FDA-2003-N-0196-0039,FDA,FDA-2003-N-0196,"Volume 8 Test Substance G 4375 Content in Rat Plasma re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:36:48Z,,0,0,090000648170431f
FDA-2003-N-0196-0044,FDA,FDA-2003-N-0196,"Volume 12 Report re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:52:30Z,,0,0,090000648170445e
FDA-2003-N-0196-0040,FDA,FDA-2003-N-0196,"Volume 7 Test Item G 4375 Content in Rat Plasma re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:37:09Z,,0,0,090000648170431e
FDA-2003-N-0196-0046,FDA,FDA-2003-N-0196,"Volume 14 Clinical Evaluation of the Cutaneous Tolerance and Acceptance of a Cosmetic Product Applied Under Normal Conditions of Use in the Sun for Three Weeks by 30 Children  re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-07-16T19:26:05Z,,0,0,0900006481704460
FDA-2003-N-0196-0045,FDA,FDA-2003-N-0196,"Volume 13 Pediatric Use Study Reports re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:57:41Z,,0,0,090000648170445f
FDA-2003-N-0196-0035,FDA,FDA-2003-N-0196,"Volume 3 Admentment No. 1 to Final Report Dated 21 March 1996 re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:24:32Z,,0,0,090000648170431a
FDA-2003-N-0196-0037,FDA,FDA-2003-N-0196,"Volume 5 Test to Evaluate PhotoAllergic in the Guinea Pig re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:30:13Z,,0,0,090000648170431c
FDA-2003-N-0196-0043,FDA,FDA-2003-N-0196,"Volume 11 English Summary of the Report re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:48:46Z,,0,0,090000648170445d
FDA-2003-N-0196-0036,FDA,FDA-2003-N-0196,"Volume 4  re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:29:41Z,,0,0,090000648170431b
FDA-2003-N-0196-0034,FDA,FDA-2003-N-0196,"Volume 2  re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:24:53Z,,0,0,0900006481704319
FDA-2003-N-0196-0042,FDA,FDA-2003-N-0196,"Volume 10 Human Safety Study Reports re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:48:37Z,,0,0,090000648170445c
FDA-2003-N-0196-0038,FDA,FDA-2003-N-0196,"Volume 6 Determination of G 4375 Content in Rat Plasma re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:30:31Z,,0,0,090000648170431d
FDA-2003-N-0196-0033,FDA,FDA-2003-N-0196,"Volume 1 Time and Extension Application re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-07-16T19:23:25Z,,0,0,0900006481704318
FDA-2003-N-0196-0041,FDA,FDA-2003-N-0196,"Volume 9 Test Report CCR Project 532003 re Data and Information from L'Oreal, USA Products, Inc.",Supporting & Related Material,Data,2014-05-19T04:00:00Z,2014,5,,,2014-05-19T22:44:43Z,,0,0,0900006481704320
FDA-2003-N-0196-0031,FDA,FDA-2003-N-0196,"Response Letter from FDA CDER to Symrise, Inc., and Ego Pharmaceuticals Ltd re  re Time and Extent Application TEA",Other,Letter(s),2014-02-28T05:00:00Z,2014,2,2014-02-28T05:00:00Z,,2014-05-14T11:33:42Z,,0,0,09000064815e9304
FDA-2003-N-0196-0030,FDA,FDA-2003-N-0196,Request for Extension from BASF AG and BASF Corporation,Other,Request for Extension,2014-02-14T05:00:00Z,2014,2,2014-02-14T05:00:00Z,,2014-02-14T20:44:26Z,,0,0,090000648048b5fd
FDA-2003-N-0196-0025,FDA,FDA-2003-N-0196,Amiloxate USP  Neo Heliopan E1000 by Symrise Safety Data Book 2,Other,References (internal) (REF),2014-01-07T05:00:00Z,2014,1,2014-01-07T05:00:00Z,,2014-01-07T21:40:26Z,,0,0,09000064814f1dc2
FDA-2003-N-0196-0027,FDA,FDA-2003-N-0196,Amiloxate USP Neo Heliopan E1000 by Symrise Safety Data Book 4,Other,References (internal) (REF),2014-01-07T05:00:00Z,2014,1,2014-01-07T05:00:00Z,,2014-02-28T18:17:37Z,,0,0,09000064814f1dc4
FDA-2003-N-0196-0024,FDA,FDA-2003-N-0196,"Amiloxate, USP - Neo Heliopan E1000 by Symrise Safety Data Book 1 (EU Commission Approval and Opinion of SCCNFP, Animal safety testing tabs 1-15)",Other,References (internal) (REF),2014-01-07T05:00:00Z,2014,1,2014-01-07T05:00:00Z,,2014-01-07T21:40:20Z,,0,0,09000064814f1dc1
FDA-2003-N-0196-0026,FDA,FDA-2003-N-0196,Amiloxate USP Neo Heliopan E1000 by Symrise Safety Data Book 3,Other,References (internal) (REF),2014-01-07T05:00:00Z,2014,1,2014-01-07T05:00:00Z,,2014-01-07T21:40:32Z,,0,0,09000064814f1dc3